EDEN: No Longer Expensive, But Not Much Incentive To Turn Bullish Either
iShares MSCI Denmark ETF remains a hold, with political uncertainty and weak consumer confidence weighing on Danish equities. EDEN's valuation has normalized, now trading at a slight discount to peers at 14.5x earnings, but lacks compelling upside catalysts. Dividend yield has improved to over 3%, yet payout sustainability is questionable due to a shift in the top holdings' capital allocation plans.
EDEN: High-Quality Companies At A Fair Price
The Danish stock market has outpaced the S&P 500 based on total return for the most of the time since its inception. Denmark is a top-grade country to own stocks in, with an AAA credit rating and a skilled workforce with 86% fluency in English. The largest (18%) holding is Novo Nordisk, but investors should be aware that most of the ETF's future results are likely to come from the other 54 stocks it holds.
EDEN: Denmark ETF Makes Sense Now (New Buy)
Investing in the iShares MSCI Denmark ETF offers exposure to undervalued international equities, focusing on healthcare, industrials, and financials sectors, which I find attractive. EDEN's concentrated portfolio, with the top 5 holdings making up 42% of the fund, allows for easier tracking and potential for strong returns. The ETF's valuation metrics—16x trailing earnings, under 2x sales, and a 4.65% yield—are compelling compared to the US market.
Eden Research: Greek authorities grant temporary approval for key product
Sustainable biopesticides specialist Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) (AIM: EDEN) said its product Cedroz has received temporary approval for use in Greece during the 2024 growing season. The go-ahead, granted under Regulation EU/1107/2009, allows Cedroz to be applied to potatoes to control wireworms, with Eastman Chemical serving as the distributor in Greece.
EDEN: Ultimately A Bet On Novo Nordisk
EDEN has a major skew towards Novo Nordisk. We aren't especially worried about Novo Nordisk's valuation, but it could never be a steal considering its coverage and fame. Crude analysis suggests growth expectations are baked in, and deceleration now as well as competitive and other exogenous risks are possible sources of disappointment.
